B Cell Malignancies
14
6
7
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
7.1%
1 terminated out of 14 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (14)
4SCAR19U T Cells Targeting B Cell Malignancies
CD19/70 Bi-specific CAR-T Cell Therapy
CD19/22 Bi-specific CAR-T Cell Therapy
CD19/79b Bi-specific CAR-T Cell Therapy
Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation